BOSTON and SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today announced that management plans to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 11:15 a.m. PST / 2:15 p.m. EST. A live and archived webcast of the pr ...

Company Overview - Rapport Therapeutics, Inc. (RAPP) currently holds a Momentum Style Score of B and a Zacks Rank of 2 (Buy) [3][4] - The company has shown strong price performance, with shares up 9.03% over the past week and 14.97% over the past month, outperforming the Zacks Medical - Biomedical and Genetics industry, which is up 5% and 3.48% respectively [6] Price Performance - Over the past quarter, RAPP shares have risen 24.16%, and over the last year, they are up 44.18%, significantly outperforming the S&P 500, which has moved 6.25% and 14.29% respectively [7] - The average 20-day trading volume for RAPP is 361,157 shares, indicating a bullish trend as the stock is rising with above-average volume [8] Earnings Outlook - In the past two months, 4 earnings estimates for RAPP have moved higher, while none have moved lower, resulting in an increase in the consensus estimate from -$3.01 to -$2.79 [10] - For the next fiscal year, 4 estimates have also moved upwards with no downward revisions during the same period, indicating positive sentiment around the company's earnings potential [10] Conclusion - Given the strong momentum indicators and positive earnings outlook, RAPP is positioned as a promising investment opportunity for those seeking stocks with potential for near-term growth [12]

Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients’ disease severity RAP-219 demonstrated meaningful improvements in patient-reported seizure severity among those with moderate or greater baseline impairment BOSTON and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (Rapport or the Company), a clinical-stage biotechnology ...

Core Viewpoint - Rapport Therapeutics, Inc. (RAPP) shares have increased by 9.5% in the last four weeks, closing at $29.43, with a potential upside of 75% based on Wall Street analysts' mean price target of $51.5 [1] Price Targets - The average price target consists of eight estimates ranging from a low of $34.00 to a high of $80.00, with a standard deviation of $13.2, indicating variability among analysts [2] - The lowest estimate suggests a 15.5% increase from the current price, while the highest estimate indicates a potential upside of 171.8% [2] Analyst Sentiment - Analysts show a consensus that RAPP will report better earnings than previously estimated, which supports the expectation of a stock price increase [4][11] - The Zacks Consensus Estimate for the current year has risen by 7.4% over the past month, with four estimates increasing and no negative revisions [12] Zacks Rank - RAPP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Price Movement Implications - While the consensus price target may not be a reliable indicator of the extent of RAPP's potential gains, it does provide a useful guide for the direction of price movement [14]

Core Insights - Rapport Therapeutics is set to present results from its Phase 2a trial of RAP-219 for focal onset seizures at the 2025 American Epilepsy Society Annual Meeting, highlighting new efficacy analyses and treatment effects [1][2]. Company Overview - Rapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders [8]. - The company's lead investigational drug, RAP-219, is designed to selectively target TARPγ8, a receptor associated protein expressed in specific brain regions, potentially offering a differentiated profile compared to traditional neuroscience medications [7][8]. Clinical Trial Details - The Phase 2a trial of RAP-219 will present topline efficacy and safety data, including the drug's effects during the first month of treatment and its consistency in efficacy throughout the treatment period [2][4]. - Additional analyses will cover the impact of baseline disease severity on efficacy outcomes and the effect of RAP-219 on seizure severity [2][6]. Presentation Schedule - The company will host a dedicated Scientific Exhibit Room at the meeting, featuring multiple poster presentations on RAP-219's clinical program [4][5]. - Specific poster sessions are scheduled for December 7 and 8, 2025, detailing various aspects of RAP-219's efficacy and safety [5][6].

Rapport Therapeutics Conference Call Summary Company Overview - **Company**: Rapport Therapeutics - **Focus**: Precision neuroscience, specifically through receptor-associated proteins - **Lead Program**: RAP-219, a TARP8 AMPA modulator targeting focal onset seizures and bipolar mania [4][5] Key Points and Arguments Product Development and Milestones - **RAP-219**: Demonstrated a best-in-class profile in focal onset seizures with a robust efficacy and tolerability profile [5][8] - **Phase Two Results**: Showed over 70% reduction in seizures over an eight-week period, with 24% of patients achieving complete seizure freedom [9][11] - **FDA Meeting**: Scheduled for Q4 2025 to discuss end of phase two results and path forward for pivotal studies in 2026 [18][19] - **Bipolar Mania Study**: Ongoing evaluation of RAP-219 with expected data in 2027 [5][6] Market Opportunity - **Focal Onset Seizures**: Approximately 1.8 million patients in the U.S. with 30-40% being treatment-resistant, representing a $10 billion-$15 billion market [11][12] - **Polypharmacy Management**: RAP-219 aims to provide a novel mechanism of action with better tolerability compared to existing treatments [12][13] - **Long-Acting Injectable (LAI)**: Development underway, expected to be transformational for patients, with potential for once-monthly or quarterly dosing [15][33][34] Safety and Efficacy - **Tolerability Profile**: RAP-219 showed no severe adverse events, with most being mild or moderate, even among patients on multiple background anti-seizure medications [9][10] - **Long Half-Life**: RAP-219 has a half-life of over 18 days, which may help prevent breakthrough seizures if doses are missed [13][28] Future Data and Expectations - **Upcoming Data Releases**: Full trial results from phase two and open-label extension study expected in 2026 [6][27] - **Phase Three Design**: Standard design anticipated, focusing on seizure reduction and responder analysis [20][21] - **Bipolar Program Read-Through**: Positive implications for RAP-219's efficacy in treating acute mania due to its mechanism targeting glutamate pathways [37][38] Additional Important Insights - **Market Research**: Indicated that RAP-219 will be utilized by both epileptologists and general neurologists across various treatment lines [14] - **Patient Population**: Phase two study included heavily treated patients, suggesting robust efficacy in difficult-to-treat populations [24] - **Regulatory Strategy**: Ongoing discussions with the FDA to align on NDA submission requirements [19][36] This summary encapsulates the critical aspects of Rapport Therapeutics' conference call, highlighting the company's strategic direction, product development, market potential, and future expectations.

Rapport Therapeutics Conference Call Summary Company Overview - Rapport Therapeutics is focused on precision neuroscience, leveraging receptor-associated proteins to enhance treatment efficacy and tolerability for patients [2][3] Key Programs - The lead program, RAP-219, is a TARP gamma-8 AMPA modulator, showing promising results in epilepsy and ongoing programs in bipolar mania [2][3] - RAP-219 has demonstrated a 78% median reduction in clinical seizure frequency and a 24% seizure freedom rate in a proof of concept study [11][12] FDA Engagement and Study Plans - The company plans to meet with the FDA by the end of 2025 for an end of phase two meeting, aiming to start phase three studies by Q3 2026 [4][5] - Two parallel registrational studies are planned, following a standard protocol for focal epilepsy [4][5] Safety and Efficacy Insights - The biological thesis focuses on modulating the AMPA receptor through TARP gamma-8, which is expressed in key brain structures related to focal seizures [6][8] - The tolerability profile from phase two data showed a 10% discontinuation rate, indicating best-in-class tolerability for anti-seizure medications [9] - Concerns regarding adverse events (AEs) related to psychiatric disorders were addressed, with no significant findings in their trials [10] Patient Population and Efficacy Expectations - The proof of concept study involved a highly refractory patient population, with 70% on three or four anti-seizure medications [16] - The efficacy results are expected to translate well into the broader phase three patient population, despite potential variability [18][13] Bipolar Mania and Other Indications - The company is exploring RAP-219 for bipolar mania, supported by the drug's mechanism targeting excitatory processes in the limbic structure [24][26] - Enrollment for the bipolar trial is progressing well, with data expected in 2027 [26] Market Opportunity - The potential market opportunity for RAP-219 in epilepsy is estimated to be multi-billion dollars, with expected utilization similar to existing treatments like Keppra [29] Upcoming Milestones - Key updates expected include the end of phase two meeting with the FDA, additional data analyses at AES in December 2025, and the initiation of phase three studies in 2026 [30][31] - The company has sufficient cash reserves, approximately $500 million, to fund operations through 2029 [32]

Core Viewpoint - Rapport Therapeutics, Inc. (RAPP) shows significant upside potential with a mean price target of $52.14, indicating a 104.5% increase from the current trading price of $25.5 [1] Price Targets and Analyst Consensus - The average price target consists of seven estimates ranging from a low of $34.00 to a high of $80.00, with a standard deviation of $14.12, suggesting variability in analyst predictions [2] - The lowest estimate indicates a 33.3% increase, while the highest suggests a 213.7% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about RAPP's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 5.2%, with three estimates moving higher and no negative revisions [12] - RAPP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are a common tool for investors, they can often mislead and should not be the sole basis for investment decisions [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Financial Performance - The company has not generated any revenue from product sales since its inception in February 2022 and has incurred significant operating losses, with net losses of $26.9 million and $17.5 million for the three months ended September 30, 2025 and 2024, respectively[146][150]. - The net loss for the three months ended September 30, 2025, was $26.925 million, compared to a net loss of $17.537 million for the same period in 2024, indicating a $9.388 million increase in losses[177]. - Net loss for the nine months ended September 30, 2025, was $77.7 million, compared to a net loss of $58.3 million in 2024, an increase of $19.4 million[183]. - Interest income decreased to $3.061 million for the three months ended September 30, 2025, down from $4.103 million in 2024, a decline of $1.042 million[177]. - Other income decreased to $3.1 million for the three months ended September 30, 2025, down from $4.1 million in 2024, primarily due to reduced interest income from lower cash and investment balances[179]. Cash and Financing - As of September 30, 2025, the company had raised aggregate gross proceeds of $711.9 million from financings and had cash, cash equivalents, and short-term investments of $513.0 million, excluding restricted cash[149]. - The company completed an underwritten public offering in September 2025, raising approximately $269.4 million in net proceeds after deducting offering costs[149]. - Net cash provided by financing activities was $270.5 million for the nine months ended September 30, 2025, primarily from the September 2025 Offering[195]. - The company believes its existing cash and cash equivalents will fund operations into the second half of 2029[153]. - The company expects its cash and cash equivalents will be sufficient to fund operating expenses and capital expenditures for at least the next 12 months[197]. Research and Development - The company plans to initiate an open-label long-term safety trial for RAP-219 by the end of 2025, with preliminary results expected in the second half of 2026[142]. - The Phase 2a trial of RAP-219 in drug-resistant focal onset seizures met its primary and secondary endpoints, demonstrating a statistically significant reduction in clinical seizures compared to baseline[142]. - The company is developing a long-acting injectable formulation of RAP-219 to improve patient adherence and expand clinical utility across indications[144]. - The Investigational New Drug application for a Phase 2 trial of RAP-219 for diabetic peripheral neuropathic pain is on clinical hold pending additional information requested by the FDA[143]. - Research and development expenses increased to $22.3 million for the three months ended September 30, 2025, compared to $15.5 million for the same period in 2024, representing a $6.7 million increase[177]. - The increase in research and development expenses included a $3.1 million rise in RAP-219 program costs, driven by clinical trial costs for the Phase 2a trial and open-label long-term safety trial[178]. - The company expects research and development expenses to increase substantially as it advances RAP-219 through clinical development and pursues regulatory approval[164]. - Research and development expenses rose to $64.5 million for the nine months ended September 30, 2025, compared to $43.7 million in 2024, marking an increase of $20.8 million[184]. - The RAP-219 program costs increased by $12.0 million, driven mainly by clinical trial costs for various Phase 2 trials[184]. Operating Expenses - Total operating expenses for the three months ended September 30, 2025, were $29.986 million, up from $21.640 million in 2024, reflecting an increase of $8.346 million[177]. - Total operating expenses for the nine months ended September 30, 2025, were $86.6 million, up from $59.5 million in 2024, reflecting a $27.1 million increase[183]. - General and administrative expenses increased to $7.7 million for the three months ended September 30, 2025, up from $6.1 million in the same period of 2024, representing a $1.6 million increase[179]. - The company anticipates that general and administrative expenses will increase due to hiring additional personnel and compliance-related costs associated with being a public company[170]. Collaborations and Agreements - The company has a collaboration agreement with Janssen Pharmaceutical NV, which includes potential milestone payments of up to $76.0 million for development and $40.0 million for sales of TARPg8 products[157]. - The company made a non-refundable payment of $1.0 million to Janssen and an additional option fee of $4.0 million, with potential milestone payments totaling up to $141.0 million for product development and sales[203]. - The company has entered into a master services agreement with NeuroPace Inc., which includes a payment of up to $5.3 million over approximately four years for services related to the RAP-219 clinical trials[161]. - Cumulative expenses incurred under the NeuroPace agreement amount to $3.4 million through September 30, 2025, with a total payment commitment of up to $5.3 million over four years[204]. Future Outlook and Risks - The company expects its expenses and operating losses to increase substantially as it continues clinical trials and research activities[151]. - The company anticipates substantial increases in expenses related to ongoing preclinical studies and clinical trials, with funding needs dependent on various factors[199]. - The company may need to raise additional capital through equity offerings or debt financings, which could dilute ownership interests and impose restrictions on operations[199]. - Future minimum operating lease payments under non-cancelable leases amount to $14.0 million, with a weighted average remaining lease term of 4.8 years[200][202]. - The company has recorded a full valuation allowance against its net deferred tax assets, indicating uncertainty about the realization of these assets[175]. - As of December 31, 2024, the company had federal net operating loss carryforwards of approximately $13.7 million and state net operating loss carryforwards of approximately $12.0 million[174]. Accounting and Compliance - The company has not experienced material changes to its critical accounting policies and estimates during the nine months ended September 30, 2025[207]. - The company has elected not to "opt out" of the extended transition period for new accounting standards, which may affect comparability with other public companies[208][209]. - The company is classified as a smaller reporting company and is not required to provide certain market risk disclosures[211].

Financial Performance - Rapport Therapeutics reported a net loss of $26.9 million for Q3 2025, compared to a net loss of $17.5 million in the same period last year, representing a 53.4% increase in losses[12] - General and Administrative (G&A) expenses increased to $7.7 million in Q3 2025 from $6.1 million in Q3 2024, reflecting a 26.2% increase[17] - Net cash used in operating activities increased to $17.465 million in Q3 2025 from $16.415 million in Q3 2024[26] - Net cash used in investing activities rose to $56.776 million in Q3 2025 compared to $53.041 million in Q3 2024[26] - Net cash provided by financing activities significantly increased to $270.533 million in Q3 2025, contrasting with a cash outflow of $1.394 million in Q3 2024[26] - The net increase in cash, cash equivalents, and restricted cash was $196.292 million in Q3 2025, compared to a decrease of $70.850 million in Q3 2024[26] Research and Development - Research and Development (R&D) expenses for Q3 2025 were $22.3 million, up from $15.5 million in Q3 2024, indicating a 43.5% increase year-over-year[12] - The Phase 2a clinical trial of RAP-219 showed a 77.8% median reduction in clinical seizures, with 24% of patients achieving seizure freedom during the 8-week treatment period[6] - Approximately 85.2% of patients in the Phase 2a trial achieved a ≥30% reduction in long episodes of seizures compared to baseline, with a p-value of <0.0001[6] - The company expects to initiate two Phase 3 pivotal trials of RAP-219 in focal onset seizures in Q3 2026[11] - The Phase 2 trial of RAP-219 in bipolar mania is currently enrolling patients, with topline results expected in the first half of 2027[7] - The company plans to develop a long-acting injectable formulation of RAP-219, with initial pharmacokinetics results expected in 2027[11] Capital and Funding - The company completed a public offering in September 2025, raising approximately $269.4 million in net proceeds[9]